

Financial news for MNTA dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for MNTA dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for MNTA dated on 2020-05-08: H.C. Wainwright Reiterates Buy on Momenta Pharmaceuticals, Raises Price Target to \$40

Financial news for MNTA dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for MNTA dated on 2020-05-07: Momenta Pharmaceuticals Q1 EPS \$(0.340) Beats \$(0.480) Estimate, Sales \$8.700M Beat \$4.330M Estimate

Financial news for MNTA dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for MNTA dated on 2020-04-14: Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for MNTA dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for MNTA dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for MNTA dated on 2020-03-16: Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for MNTA dated on 2020-03-12: Goldman Sachs Initiates Coverage On Momenta Pharmaceuticals with Neutral Rating, Announces \$29 Price Target

Financial news for MNTA dated on 2020-03-02: Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears.

Financial news for MNTA dated on 2020-02-26: Cantor Fitzgerald Reiterates Neutral on Momenta Pharmaceuticals, Raises Price Target to \$30

Financial news for MNTA dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for MNTA dated on 2020-02-26: Momenta Pharmaceuticals Q4 EPS \$(0.85) Misses \$(0.56) Estimate, Sales \$8.182M Beat \$5.56M Estimate

Financial news for MNTA dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for MNTA dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for MNTA dated on 2020-02-21: The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

Financial news for MNTA dated on 2020-02-20: Stocks That Hit 52-Week Highs On Thursday

Financial news for MNTA dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for MNTA dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for MNTA dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for MNTA dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for MNTA dated on 2020-01-28: Momenta Pharmaceuticals shares are trading higher after Stifel maintained a Buy rating on the stock and raised the price target from \$29 to \$43.

Financial news for MNTA dated on 2020-01-28: Stifel Maintains Buy on Momenta Pharmaceuticals, Raises Price Target to \$43

Financial news for MNTA dated on 2020-01-21: Momenta Pharmaceuticals shares are trading lower in sympathy with the broader market as anxiety around the coronavirus outbreak in China spreads to global markets. NOTE: Leaders at Davos have doubts a phase 2 U.S.-China deal will be reached before Trump's term.

Financial news for MNTA dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for MNTA dated on 2020-01-16: 75 Biggest Movers From Yesterday

Financial news for MNTA dated on 2020-01-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for MNTA dated on 2020-01-15: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MNTA dated on 2020-01-15: Benzinga's Top Upgrades, Downgrades For January 15, 2020

Financial news for MNTA dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for MNTA dated on 2020-01-15: 34 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for MNTA dated on 2020-01-15: 21 Stocks Moving in Wednesday's Pre-Market Session

Financial news for MNTA dated on 2020-01-15: Momenta Pharmaceuticals shares are trading higher after JP Morgan analysts upgraded the company's stock from Neutral to Overweight and announced a \$30 price target.

Financial news for MNTA dated on 2020-01-15: JP Morgan Upgrades Momenta Pharmaceuticals to Overweight, Announces \$30 Price Target

Financial news for MNTA dated on 2020-01-15: 80 Biggest Movers From Yesterday

Financial news for MNTA dated on 2020-01-14: 48 Stocks Moving In Tuesday's Mid-Day Session

Financial news for MNTA dated on 2020-01-13: Momenta Expects \$545.1M In Cash, Cash Equivalents, And Marketable Securities At Year-end 2019; Sees FY20 Non-GAAP Operating Expense \$220M-\$240M

Financial news for MNTA dated on 2020-01-03: Momenta Pharma Names Young Kwon CFO

Financial news for MNTA dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for MNTA dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for MNTA dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for MNTA dated on 2019-12-23: Stocks That Hit 52-Week Highs On Monday

Financial news for MNTA dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for MNTA dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for MNTA dated on 2019-12-19: The Daily Biotech Pulse: Seattle

Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for MNTA dated on 2019-12-18: Stocks That Hit 52-Week Highs On Wednesday

Financial news for MNTA dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for MNTA dated on 2019-12-12: Momenta Pharma Prices ~14.5M Common Shares At \$15.50/Share

Financial news for MNTA dated on 2019-12-12: 13 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for MNTA dated on 2019-12-12: 70 Biggest Movers From Yesterday

Financial news for MNTA dated on 2019-12-11: 50 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MNTA dated on 2019-12-11: 32 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MNTA dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for MNTA dated on 2019-12-10: Momenta Pharma shares are trading lower after the company reported a \$200 million common stock offering.

Financial news for MNTA dated on 2019-12-10: Momenta Pharma Reports \$200M Common Stock Offering

Financial news for MNTA dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for MNTA dated on 2019-12-06: Momenta Pharmaceuticals Option Alert: Jan 17 \$18 Calls Sweep (33) near the Ask: 800 @ \$1.155 vs 0 OI; Ref=\$17.92

Financial news for MNTA dated on 2019-11-27: The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

Financial news for MNTA dated on 2019-11-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for MNTA dated on 2019-11-15: Momenta Pharm 8-K Shows Co. Confirmed First Patient In Unity Study Of M281 In Hemolytic Disease Of Fetus, Newborn Delivered Full-Term Baby

Financial news for MNTA dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecetra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for MNTA dated on 2019-11-12: Benzinga's Top Upgrades, Downgrades For November 12, 2019

Financial news for MNTA dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On Momenta Pharmaceuticals with Buy Rating, Announces \$29 Price Target

Financial news for MNTA dated on 2019-11-08: Stocks That Hit 52-Week Highs On Friday

Financial news for MNTA dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for MNTA dated on 2019-11-06: Benzinga's Top Upgrades, Downgrades For November 6, 2019

Financial news for MNTA dated on 2019-11-06: Wells Fargo Initiates Coverage On Momenta Pharmaceuticals with Outperform Rating

Financial news for MNTA dated on 2019-10-31: Momenta Pharmaceuticals Q3 EPS \$(0.45) Beats \$(0.5) Estimate, Sales \$6.39M Beat \$5.24M Estimate

Financial news for MNTA dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for MNTA dated on 2019-09-25: Momenta Pharmaceuticals shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a price target of \$24 per share.

Financial news for MNTA dated on 2019-09-25: Benzinga's Top Upgrades, Downgrades For September 25, 2019

Financial news for MNTA dated on 2019-09-25: HC Wainwright & Co. Initiates Coverage On Momenta Pharmaceuticals with Buy Rating, Announces \$24 Price Target

Financial news for MNTA dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for MNTA dated on 2019-08-02: Momenta Pharmaceuticals Q2 EPS \$(1.16) Misses \$(0.43) Estimate, Sales \$5.182M Miss \$9.2M Estimate

Financial news for MNTA dated on 2019-07-30: Momenta Pharma Reports Fast Track Designation For M281 In Hemolytic Disease Of The Fetus, Newborn

Financial news for MNTA dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for MNTA dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for MNTA dated on 2019-06-19: Momenta Pharma Reports Settlement Deal With Amphastar Resolving Enoxaparin Sodium Injection Litigation

Financial news for MNTA dated on 2019-05-02: Momenta Pharmaceuticals Q1 EPS \$(0.46) Misses \$(0.43) Estimate, Sales \$4.113M Miss \$10.12M Estimate

Financial news for MNTA dated on 2019-03-28: Momenta Pharmaceuticals Announces Presentations At American Association For Cancer Research Annual Meeting 2019

Financial news for MNTA dated on 2019-03-21: Momenta Pharma Highlights Publication Of New Data Supporting M281 As First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta

Financial news for MNTA dated on 2019-03-18: Benzinga's Top Upgrades, Downgrades For March 16, 2019

Financial news for MNTA dated on 2019-03-18: BTIG Research Initiates Coverage On Momenta Pharmaceuticals with Neutral Rating

Financial news for MNTA dated on 2019-02-22: The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

Financial news for MNTA dated on 2019-02-22: Momenta Pharmaceuticals Q4 EPS \$(0.10) Down From \$0.18 YoY, Sales \$10.8M Miss \$17.11M Estimate

Financial news for MNTA dated on 2019-02-22: Earnings Scheduled For February 22, 2019

Financial news for MNTA dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for MNTA dated on 2019-01-30: Momenta Pharmaceuticals Stockholders Approved Amendment To Increase Number Of Authorized Shares Of Co.'s Common Stock From 100M To 200M

Financial news for MNTA dated on 2019-01-29: Momenta Pharmaceuticals Announces First Subject Dosed In Phase 1/2 Clinical Trial Of M254, Hypersialylated Immunoglobulin G

Financial news for MNTA dated on 2019-01-04: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for MNTA dated on 2018-12-12: 48 Biggest Movers From Yesterday

Financial news for MNTA dated on 2018-12-10: 48 Biggest Movers From Friday

Financial news for MNTA dated on 2018-12-07: The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

Financial news for MNTA dated on 2018-12-06: Momenta Pharmaceuticals Prices 17.3M Share Public Offering of Common Stock @\$11.50/Share

Financial news for MNTA dated on 2018-12-06: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

Financial news for MNTA dated on 2018-12-03: Momenta Pharmaceuticals Says Will Be Able To Commercialize M923 In The US, Pending Regulatory Pathway, As Early As November 20, 2023

Financial news for MNTA dated on 2018-11-28: Stocks Which Set New 52-Week Low

Yesterday Tues., Nov. 27, 2018

Financial news for MNTA dated on 2018-11-28: The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

Financial news for MNTA dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for MNTA dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for MNTA dated on 2018-11-07: Momenta Pharmaceuticals, Inc. Q3 Adj. EPS \$(0.45) Beats \$(0.54) Estimate, Sales \$14.884M Miss \$17.55M Estimate

Financial news for MNTA dated on 2018-11-06: AbbVie Announces HUMIRA Global Patent License With Momenta

Financial news for MNTA dated on 2018-11-05: PiperJaffray Initiates Coverage On Momenta Pharmaceuticals with Overweight Rating, Announces \$35 Price Target

Financial news for MNTA dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for MNTA dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for MNTA dated on 2018-10-15: 44 Biggest Movers From Yesterday

Financial news for MNTA dated on 2018-10-12: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for MNTA dated on 2018-10-12: 44 Biggest Movers From Yesterday

Financial news for MNTA dated on 2018-10-01: Momenta Sees Added Captial Raise To Fund Ongoing Programs Over Next 2 Years

Financial news for MNTA dated on 2018-10-01: Momenta Sees Restructuring Plan Costing \$17M-\$20M Through 2018

Financial news for MNTA dated on 2018-10-01: Momenta Pharma Sees Realizing ~\$250M In Cost Savings Over 5-Year Plan Related To Restructuring, Elimination Of Programs, 110 Positions

Financial news for MNTA dated on 2018-10-01: Momenta Pharma Approved Plan To Restructure Exec Team, Reduce Workforce By ~50%

Financial news for MNTA dated on 2018-10-01: Momenta Pharma Has Initiated Discussions With Its Collaboration Partner, Mylan, To Exit Its Participation In Development Of Its Other 5 Biosimilar Programs Including M834, Intends To Focus Solely On Continued Development Of M710

Financial news for MNTA dated on 2018-10-01: Momenta Pharma Sees Filing Biologics License Application For M923 With FDA

Financial news for MNTA dated on 2018-10-01: Momenta Pharma Reports Completion Of Strategic Review, Will 'Prioritize Pipeline of Novel Drug Candidates for Immune-Mediated Diseases and Reduce Investment in Biosimilars by Focusing on Two Later-stage Assets'

Financial news for MNTA dated on 2018-08-09: Momenta Pharmaceuticals shares are trading 7.4% lower to \$26.03 after drastic earnings miss.

Financial news for MNTA dated on 2018-08-09: Momenta Says FY18 Opex Guidance Is No Longer Accurate Due To Co.'s Ongoing Strategic Review; Co. Plans To Update FY18 Opex Guidance When It Reports Q3 Results

Financial news for MNTA dated on 2018-08-09: Momenta Pharmaceuticals Q2 EPS \$(0.91) Misses \$(0.41) Estimate, Sales \$13.031M Miss \$21.05M Estimate

Financial news for MNTA dated on 2018-07-26: Stocks Which Set New 52-Week High Yesterday, July 25th

Financial news for MNTA dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for MNTA dated on 2018-07-20: Stocks Which Set New 52-Week High Yesterday

Financial news for MNTA dated on 2018-07-19: Benzinga's Daily Biotech Pulse: Novartis

Licenses Skin Drug, 2 Stocks To Debut

Financial news for MNTA dated on 2018-07-18: Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

Financial news for MNTA dated on 2018-07-13: Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Financial news for MNTA dated on 2018-06-28: Momenta Pharmaceuticals And Human Genome Sciences Have Come To An Understanding Regarding A Prior Contract Dispute; As Part Of The Dispute, Momenta Will Pay Human Genome Sciences \$15M By Aug. 15, 2018 And \$15M By July 1, 2019

Financial news for MNTA dated on 2018-06-11: Cantor Fitzgerald Initiates Coverage On 8 Pharma/Biotech Stocks After Hours: 7 With Overweight, 1 With Neutral Rating

Financial news for MNTA dated on 2018-05-24: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Financial news for MNTA dated on 2018-05-23: Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Financial news for MNTA dated on 2018-05-18: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Financial news for MNTA dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for MNTA dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for MNTA dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for MNTA dated on 2018-05-08: Momenta Sees Continuing To Recognize Sales From Mylan's \$45M Upfront Payment On Quarterly Basis, Sees Collab. Reimbursement Sales \$0-\$2M

Financial news for MNTA dated on 2018-05-08: Momenta Sees Q2 Adj. Operating Expense \$45M-\$55M; FY18 Adj. Opex \$180M-\$220M

Financial news for MNTA dated on 2018-05-08: Momenta Pharmaceuticals Q1 EPS \$(0.63) Misses \$(0.48) Estimate, Sales \$4.85M Miss \$18.45M Estimate

Financial news for MNTA dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for MNTA dated on 2018-05-03: Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

Financial news for MNTA dated on 2018-04-12: Mylan Inks Deal With Mapi Pharma For Multiple Sclerosis Drug

Financial news for MNTA dated on 2018-03-21: Amphastar Pharmaceuticals Says U.S. District Court Entered Final Judgement In Favor Of Co. In A Lawsuit Brought By Momenta Pharmaceuticals

Financial news for MNTA dated on 2018-03-06: Morgan Stanley: As Generic Competitors Falter, Mylan Is Worth A Shot

Financial news for MNTA dated on 2018-02-22: Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy

Financial news for MNTA dated on 2018-02-22: Benzinga's Top Upgrades, Downgrades For February 22, 2018

Financial news for MNTA dated on 2018-02-22: Stifel Nicolaus Upgrades Momenta Pharmaceuticals to Buy

Financial news for MNTA dated on 2018-02-21: Momenta Pharma Reports Q4 EPS \$0.18 vs \$(0.31) Est., Sales \$64.61M vs \$66.58M Est., May Not Compare

Financial news for MNTA dated on 2018-02-19: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for MNTA dated on 2018-02-13: Momenta Pharmaceuticals Announces FDA Approval, Launch of Glatopa (glatiramer acetate injection) 40 mg/mL

Financial news for MNTA dated on 2018-01-30: Momenta Pharmaceuticals Shares Up 7%

Following News Compliance Status For Co.'s McPherson, Kansas Facility Was Amended To Voluntary Action Indicated, Suggesting 'potential for the near-term FDA approval of Sandoz's Glatopa 40 mg ANDA'

Financial news for MNTA dated on 2018-01-30: Momenta Pharma Reports McPherson, Kansas Facility Compliance Status Amended To VAI, Provides 'the potential for the near-term FDA approval of Sandoz's Glatopa 40 mg ANDA'

Financial news for MNTA dated on 2018-01-19: Momenta Trade Resumes, Up 10.2% At \$16.75

Financial news for MNTA dated on 2018-01-19: Momenta Pharma Shares Halted On Circuit Breaker, Up 14.52%

Financial news for MNTA dated on 2018-01-09: Teva's Cost-Cutting Plan Nets A Mizuho Upgrade

Financial news for MNTA dated on 2018-01-09: 48 Biggest Movers From Yesterday

Financial news for MNTA dated on 2018-01-08: 40 Biggest Movers From Friday

Financial news for MNTA dated on 2018-01-05: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for MNTA dated on 2018-01-05: Momenta Pharma Offers Top-Line Phase 1 Data Showing Proof Of Mechanism For M281: Showed Safety, Tolerability With No Adverse Events

Financial news for MNTA dated on 2018-01-03: 9 Stocks Moving In Wednesday's After-Hours Session

Financial news for MNTA dated on 2018-01-03: Momenta and Mylan Announce Development Strategy for M710, Plan To Initiate Pivotal Clinical Trial In 1H18

Financial news for MNTA dated on 2017-12-08: 23 Stocks Moving In Friday's Pre-Market Session

Financial news for MNTA dated on 2017-11-01: Momenta Pharma Reports Q3 EPS \$(0.44) vs \$(0.46) Est., Sales \$24.1M vs \$30.6M Est.

Financial news for MNTA dated on 2017-11-01: Momenta, Mylan On M834 Say, 'Momenta and Mylan continue to gather and analyze these data to inform next steps for the program'

Financial news for MNTA dated on 2017-11-01: Momenta Pharma, Mylan Report Initial Results From Phase 1 Trial For M834: Did Not Meet Primary Endpoints

Financial news for MNTA dated on 2017-10-05: 20 Biggest Mid-Day Losers For Thursday

Financial news for MNTA dated on 2017-10-05: The Market In 5 Minutes: Shopify, Equifax And More

Financial news for MNTA dated on 2017-10-05: Benzinga's Top Upgrades, Downgrades For October 5, 2017

Financial news for MNTA dated on 2017-10-05: Momenta Pharma Could Face Pressure Following Approval Of Mylan's Generic Copaxone

Financial news for MNTA dated on 2017-10-05: Stifel Nicolaus Downgrades Momenta Pharmaceuticals to Hold

Financial news for MNTA dated on 2017-10-04: Momenta Pharma Shares Were Unaffected Following Late Afternoon Downgrade From Buy To Hold By Stifel

Financial news for MNTA dated on 2017-10-04: 18 Biggest Mid-Day Losers For Wednesday

Financial news for MNTA dated on 2017-10-04: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MNTA dated on 2017-10-02: Momenta Pharma Promotes Ganesh Kaundinya To Roles Of COO, Chief Scientific Officer

Financial news for MNTA dated on 2017-09-28: Goldman Sachs Initiates Coverage On Momenta Pharmaceuticals with Neutral Rating, Announces \$18.00 Price Target

Financial news for MNTA dated on 2017-08-02: Momenta Pharmaceuticals Reports Q2 EPS \$(0.50) vs \$(0.50) Est., Sales \$23.57M vs \$24.64M Est.

Financial news for MNTA dated on 2017-07-21: UPDATE: Momenta Pharma Issues Release Confirming Earlier Reports Of Court Ruling In Favor Of Amphastar Pharma In Generic

Lovenox Patent Case; Co. Says Its Patent Was Infringed, But Found To Be Invalid And Unenforceable

Financial news for MNTA dated on 2017-07-21: U.S. Jury Clears Amphastar Pharmaceuticals inc In Patent Lawsuit By Momenta Pharmaceuticals Inc

Financial news for MNTA dated on 2017-06-01: Momenta Pharmaceuticals Names Dr. Santiago Arroyo Chief Medical Officer

Financial news for MNTA dated on 2017-05-22: 12 Biggest Mid-Day Losers For Monday

Financial news for MNTA dated on 2017-05-22: Benzinga's Top Upgrades, Downgrades For May 22, 2017

Financial news for MNTA dated on 2017-05-22: Barclays Downgrades Momenta Pharmaceuticals to Equal-Weight

Financial news for MNTA dated on 2017-05-02: Momenta Pharmaceuticals Reports Q1 EPS \$(0.46) vs \$(0.66) Est., Sales \$26.6M vs \$24.4M Est.

Financial news for MNTA dated on 2017-03-08: 8-K from Momenta Pharma Shows US Court of Appeals for First Circuit Reversed District Court's Dismissal, Remanded Suit Brought by Amphastar for Further Proceedings

Financial news for MNTA dated on 2017-02-22: Benzinga's Top Upgrades, Downgrades For February 22, 2017

Financial news for MNTA dated on 2017-02-22: Leerink Swann Downgrades Momenta Pharmaceuticals to Market Perform

Financial news for MNTA dated on 2017-02-21: 15 Biggest Mid-Day Losers For Tuesday

Financial news for MNTA dated on 2017-02-21: Mid-Morning Market Update: Markets Open Higher; Wal-Mart Earnings Beat Views

Financial news for MNTA dated on 2017-02-21: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for MNTA dated on 2017-02-21: Momenta Pharmaceuticals Reports Q4 EPS \$0.60 Does Not Compare To \$(0.24) Est., Revenue \$34.19M vs. \$29.5M Est.

Financial news for MNTA dated on 2017-02-17: Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa Fill/Finish Manufacturer

Financial news for MNTA dated on 2017-02-17: Momenta Pharma Reports HSR Clearance for Collab, License Deal with CSL; CSL Will Pay \$50M Upfront cash Payment

Financial news for MNTA dated on 2017-01-31: A District Court's Ruling Against Teva Pharma Opens The Door For Generics

Financial news for MNTA dated on 2017-01-31: Mid-Afternoon Market Update: Under Armour Drops On Earnings Miss; Jaguar Animal Health Shares Climb

Financial news for MNTA dated on 2017-01-31: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for MNTA dated on 2017-01-31: Mid-Morning Market Update: Markets Open Lower; Mastercard Earnings Beat Views

Financial news for MNTA dated on 2017-01-31: Momenta Pharma Reports District Court Decision to Invalidate Teva's Patents in COPAXONE 40 mg/ML Litigation

Financial news for MNTA dated on 2017-01-17: Option Alert: Momenta Feb \$18 Call; 3150 @Bid @\$0.50; Ref=\$15.22

Financial news for MNTA dated on 2017-01-05: Momenta Shares Resume, Move Higher, Now Up 10%

Financial news for MNTA dated on 2017-01-05: Momenta Pharma Shares to Resume Trade at 4:30 p.m. EST

Financial news for MNTA dated on 2017-01-05: UPDATE: Momenta Will Receive Upfront License Fee Payment of \$50M, Up to \$550M in Potential Milestone Payments from CSL

Financial news for MNTA dated on 2017-01-05: Momenta Announces Collaboration, License Deal with CSL for Development of Fc Multimer Programs, Including M230

Financial news for MNTA dated on 2017-01-05: Momenta Pharma Shares Halted News Pending



Financial news for MNTA dated on 2017-01-03: Momenta Pharmaceuticals, Baxalta Entered into Asset Return and Termination Agreement

Financial news for MNTA dated on 2016-12-22: Momenta Pharma Shares Sell Off Below \$15.20 Level as Hearing Co. Has Lost Patent Challenge Against Bristol-Myers Related to '239 Orencia Patent

Financial news for MNTA dated on 2016-12-05: What Is The ASH Conference And Why Should Biotech Investors Care?

Financial news for MNTA dated on 2016-11-29: CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup

Financial news for MNTA dated on 2016-11-29: Momenta Pharmaceuticals Announces Phase 3 M923 Met Primary Endpoint and All Secondary Endpoints

Financial news for MNTA dated on 2016-11-22: Benzinga's Top Initiations

Financial news for MNTA dated on 2016-11-22: Aegis Capital Initiates Coverage On Momenta Pharmaceuticals, Inc. - Common Stock at Hold, Announces \$15.00 Target

Financial news for MNTA dated on 2016-11-17: Momenta Pharmaceuticals Announces Publication on the Design of M230, a Novel Autoimmune Disease Drug Candidate, in Science Translational Medicine

Financial news for MNTA dated on 2016-11-16: Morgan Stanley Cuts Teva's Price Target By 33%

Financial news for MNTA dated on 2016-11-02: Momenta Pharmaceuticals Reports Q3 EPS \$(0.26) vs. Est. \$(0.30), Rev. \$29.1M vs. Est. \$25.68M

Financial news for MNTA dated on 2016-11-02: Momenta and Mylan Initiate Phase 1 Clinical Trial for M834

Financial news for MNTA dated on 2016-11-02: Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer

Financial news for MNTA dated on 2016-10-24: Goldman Says These 25 Healthcare Stocks Are Immune To The Election

Financial news for MNTA dated on 2016-10-12: 5 Stocks Which Rallied Three Days On Increasing Volume

Financial news for MNTA dated on 2016-10-11: A Compelling Risk/Reward Seen In Momenta Pharmaceuticals

Financial news for MNTA dated on 2016-10-11: 8 Biggest Mid-Day Gainers For Tuesday

Financial news for MNTA dated on 2016-10-11: Benzinga's Volume Movers

Financial news for MNTA dated on 2016-10-11: Mid-Morning Market Update: Markets Open Lower; Alcoa Misses Q3 Views

Financial news for MNTA dated on 2016-10-11: 8 Biggest Price Target Changes For Tuesday

Financial news for MNTA dated on 2016-10-11: Benzinga's Top Upgrades

Financial news for MNTA dated on 2016-10-11: Barclays Upgrades Momenta Pharmaceuticals, Inc. - Common Stock to Overweight, Raises to \$19.00

Financial news for MNTA dated on 2016-09-27: 8-K from Momenta Pharma Shows Details of Deal with Baxalta: Received Initial Cash Payment of \$33M, \$7M License Payment, \$12M Technical, Development Milestone Payments

Financial news for MNTA dated on 2016-09-27: Momenta Pharma Reports Regained Global Development, Commercialization Rights to M923; Terminates Collaboration Deal with Baxalta

Financial news for MNTA dated on 2016-09-08: Watch These 5 Huge Put Purchases In Thursday Trade

Financial news for MNTA dated on 2016-09-07: 15 Biggest Mid-Day Losers For Wednesday

Financial news for MNTA dated on 2016-09-07: Option Alert: MNTA Sep16 10.0 Puts Sweep: 543 @ ASK \$0.40: 565 traded vs 2723 OI: \$11.22 Ref

Financial news for MNTA dated on 2016-09-07: Benzinga's Top Downgrades

Financial news for MNTA dated on 2016-09-07: Maxim Group Downgrades Momenta Pharmaceuticals to Sell

Financial news for MNTA dated on 2016-08-24: Traders Attributing Recent Moves Lower in Teva, Momenta to Report Final Decision on Patent '250 Copaxone Showed Claims Invalidated

Financial news for MNTA dated on 2016-08-24: Momenta Pharma Spikes to High of \$12.88 on Volume

Financial news for MNTA dated on 2016-08-04: Momenta Pharmaceuticals Reports Q2 EPS \$(0.31) vs. Est. \$(0.34), Rev. \$26.4M vs. Est. \$22.9M

Financial news for MNTA dated on 2016-08-04: Momenta Reports Discontinuation of Further Accrual of Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer

Financial news for MNTA dated on 2016-06-09: Momenta Pharmaceuticals Initiates Phase 1 Trial of M281

Financial news for MNTA dated on 2016-06-06: Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'

Financial news for MNTA dated on 2016-06-06: Goldman Sachs Initiates Coverage on Momenta Pharmaceuticals at Neutral, Announces \$14.00 PT

Financial news for MNTA dated on 2016-06-04: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at #ASCO16

Financial news for MNTA dated on 2016-05-03: Momenta Pharma Reports Q1 EPS \$(0.35) vs \$(0.32) Est., Sales \$19.9M vs \$28M Est.

Financial news for MNTA dated on 2016-02-29: Stocks Hitting 52-Week Lows

Financial news for MNTA dated on 2016-02-18: Momenta Pharma Reports Q4 EPS \$(0.43) vs \$(0.04) Est., Sales \$22.4M vs \$30.4M Est.

Financial news for MNTA dated on 2016-01-08: Momenta Spikes Higher on Volume

Financial news for MNTA dated on 2016-01-08: Mylan, Momenta Pharma Report Global Collab for Joint Development, Commercialization of Six Biosimilar Products

Financial news for MNTA dated on 2015-12-07: Momenta Pharmaceuticals Names Matthew P. Ottmer as COO

Financial news for MNTA dated on 2015-11-23: Benzinga's Top Initiations

Financial news for MNTA dated on 2015-11-23: Barclays Initiates Coverage on Momenta Pharmaceuticals at Equal-weight, Announces \$22.00 PT

Financial news for MNTA dated on 2015-11-13: Benzinga's Top Initiations

Financial news for MNTA dated on 2015-11-13: Momenta Reports Temporary Pause of Patient Enrollment in the Necuparanib Phase 2 Study

Financial news for MNTA dated on 2015-11-13: JP Morgan Initiates Coverage on Momenta Pharmaceuticals at Overweight, Announces \$26.00 PT

Financial news for MNTA dated on 2015-11-10: Momenta Pharma Reports US Court of Appeals Decision to Remand Enoxaparin Case Back to District Court

Financial news for MNTA dated on 2015-11-04: Momenta Pharma Reports Q3 Loss of \$0.44/Share vs Loss of \$0.12/Share Est., Sales \$13.8M vs \$29M Est.

Financial news for MNTA dated on 2015-10-05: Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You

Financial news for MNTA dated on 2015-10-05: Baxalta Announces Initiation of M923 Clinical Trial with Momenta

Financial news for MNTA dated on 2015-10-05: Baxalta and Momenta Announce Initiation of Pivotal Clinical Trial for M923, a Biosimilar Version of HUMIRA (adalimumab)

Financial news for MNTA dated on 2015-08-20: The Coming Drug-Patent Cliff Is Pushing This Portfolio Up

Financial news for MNTA dated on 2015-08-06: Benzinga's Top Downgrades

Financial news for MNTA dated on 2015-08-06: Goldman Sachs Downgrades Momenta

Pharmaceuticals to Neutral, Maintains \$27.00 PT

Financial news for MNTA dated on 2015-08-04: Momenta Pharma Reports Q2 Loss \$0.04 May Not Compare, Sales \$44.9M

Financial news for MNTA dated on 2015-07-02: Thursday's Mid-Day Movers: Real Good Solar, Xoom, ConforMIS, Health Net And More

Financial news for MNTA dated on 2015-07-02: UBS Downgrades Momenta Pharmaceuticals to Sell, Raises PT to \$17.00

Financial news for MNTA dated on 2015-06-25: Momenta Pharmaceuticals Announces CFO Retirement and Succession Plan

Financial news for MNTA dated on 2015-06-18: Momenta Pharmaceuticals Reports Launch of Glatopa, the First Substitutable Generic for COPAXONE 20mg, First Commercial Sale Will Trigger \$10M Milestone Payment

Financial news for MNTA dated on 2015-06-18: Momenta Pharma Reports CAFC Decision TO Invalidate Remanded Teva Pharma Patent In COPAXONE 20 mg Suit

Financial news for MNTA dated on 2015-06-04: Stifel Nicolaus Initiates Momenta Pharmaceuticals At Buy

Financial news for MNTA dated on 2015-06-04: Benzinga's Top Initiations

Financial news for MNTA dated on 2015-06-04: Momenta Pharmaceuticals Reports Oral, Poster Presentations Relating to Novel Autoimmune Programs at EULAR 2015

Financial news for MNTA dated on 2015-06-04: Momenta Pharmaceuticals Announces Oral and Poster Presentations Relating to Novel Autoimmune Programs at EULAR 2015

Financial news for MNTA dated on 2015-06-04: Stifel Nicolaus Initiates Coverage on Momenta Pharmaceuticals at Buy, Announces \$26.00 PT

Financial news for MNTA dated on 2015-06-01: 16 Biotech Stocks Moving Off The ASCO Conference

Financial news for MNTA dated on 2015-06-01: Momenta Pharmaceuticals to Report New Data From Phase 1 Trial of Necuparanib in Pancreatic Cancer Patients

Financial news for MNTA dated on 2015-05-20: Momenta Pharmaceuticals Prices 7.25M Share Offering @\$19.00/Share

Financial news for MNTA dated on 2015-05-18: Momenta Pharma. Reports Offering Of 7.25M Shares

Financial news for MNTA dated on 2015-05-18: Momenta Pharma Reports Data Presentation on M402 at ASCO Meeting

Financial news for MNTA dated on 2015-05-11: Stocks Hitting 52-Week Highs

Financial news for MNTA dated on 2015-05-01: Momenta Reports Q1 Loss of \$0.04/Share vs Loss of \$0.44/Share Est., Sales \$8.6M vs \$11.73M Est.

Financial news for MNTA dated on 2015-04-21: 8-K from Momenta Pharma Shows Co. Will Sell Up to \$75M via ATM Equity Offering

Financial news for MNTA dated on 2015-04-17: Momenta Pharmaceuticals To Present Data on Glatopa (glatiramer acetate injection) at the American Academy of Neurology's 2015 Annual Meeting

Financial news for MNTA dated on 2015-04-16: Momenta Pharmaceuticals Spikes Up Following FDA News On Copaxone

Financial news for MNTA dated on 2015-04-16: Hearing Momenta Has Requested Expedited Court Decision Related to Copaxone

Financial news for MNTA dated on 2015-04-16: UPDATE: Momenta Eligible For Milestone Payments Of Potentially \$140M

Financial news for MNTA dated on 2015-04-16: Momenta Pharma Announces FDA Approval Of ANDA For Glatopa, First Substitute Generic For Copaxone

Financial news for MNTA dated on 2015-04-16: Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa

Financial news for MNTA dated on 2015-04-16: Mylan Shares Spike Higher on Teva News

Financial news for MNTA dated on 2015-04-16: FDA Denies Teva Petition TO Block Generic Copaxone, Momenta Moving Higher On News

Financial news for MNTA dated on 2015-04-16: Momenta Shares Spike Higher

Financial news for MNTA dated on 2015-03-31: Benzinga's M&A Chatter for Tuesday March 31, 2015

Financial news for MNTA dated on 2015-03-31: Teva Declines Comment on Earlier Report of Potential Takeover Talks With Momenta

Financial news for MNTA dated on 2015-03-31: Hearing The Deal Says Momenta Takeover Target for Actavis, Teva

Financial news for MNTA dated on 2015-03-02: Momenta Pharmaceuticals Announces Preclinical Studies Revealing Development of a Novel Process to Generate High-Quality Hyper-sialylated IVIg Drug Candidate in PNAS

Financial news for MNTA dated on 2015-02-17: Baxter International Notified Momenta that it was Terminating in Part the Development, License and Option Agreement dated December 22, 2011 between Momenta and Baxter -8K

Financial news for MNTA dated on 2015-02-17: Momenta Pharma Reports Q4 EPS Loss \$0.31 Vs Est Loss \$0.26, Sales \$16M Vs Est \$23.80M

Financial news for MNTA dated on 2015-02-17: Earnings Scheduled For February 17, 2015

Financial news for MNTA dated on 2015-02-04: Momenta Pharmaceuticals: Is Overdependence On Enoxaparin A Cause For Concern?

Financial news for MNTA dated on 2015-01-23: Maxim Group Downgrades Momenta Pharmaceuticals to Sell

Financial news for MNTA dated on 2015-01-21: Momenta Pharmaceuticals Announces Supreme Court Decision to Remand Generic Copaxone(R) Case Back to CAFC

Financial news for MNTA dated on 2015-01-20: Supreme Court Sends MS Drug Patent Case Back to Lower Court in Win for Teva

Financial news for MNTA dated on 2015-01-13: Option Alert: Momenta Mar \$16 Call; 1,871 Contract Trade at Ask @\$0.60; Currently \$12.16

Financial news for MNTA dated on 2015-01-07: Notable Option Activity For January 7

Financial news for MNTA dated on 2015-01-07: Option Alert: Momenta Jan \$13 Call; 1,931 Contract Trade Above Ask @\$0.43; Currently \$12.72

Financial news for MNTA dated on 2014-12-01: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer

Financial news for MNTA dated on 2014-12-01: Momenta Pharma Reports Acceptance of Clinical Trial App in Europe for M923, Co. Will Receive Payment in Dec. '14

Financial news for MNTA dated on 2014-12-01: Momenta Pharmaceuticals Announces Acceptance Of A Clinical Trial Application In Europe for M923, A Biosimilar Version Of Humira

Financial news for MNTA dated on 2014-11-05: Momenta Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.56) vs \$(0.43) Est; Revenue of \$9.30M vs \$13.03M Est

Financial news for MNTA dated on 2014-10-22: Momenta Spikes Lower

Financial news for MNTA dated on 2014-10-13: Stocks Hitting 52-Week Lows

Financial news for MNTA dated on 2014-10-09: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial Of Necuparanib In Patients With Pancreatic Cancer

Financial news for MNTA dated on 2014-09-08: Momenta Pharmaceuticals Exercises Option To Acquire Novel Antibody Program From AnaptysBio

Financial news for MNTA dated on 2014-08-28: Mylan Release Confirms ANDA for Three-Times-Per-Week Generic Copaxone Accepted

Financial news for MNTA dated on 2014-08-28: Momenta Pharma Announces ANDA for Three-Times-A-Week Generic Copaxone Accepted

Financial news for MNTA dated on 2014-07-31: Momenta Pharmaceuticals, Inc. Reports Q2

EPS of \$(0.51) vs \$(0.46) Est; Revenue of \$11.0M vs \$11.22M Est

Financial news for MNTA dated on 2014-06-05: Momenta Receives Orphan Designation for Necuparanib in Pancreatic Cancer

Financial news for MNTA dated on 2014-06-02: Goldman Sachs Initiates Coverage on Momenta Pharmaceuticals, Inc. at Buy, Announces \$19.00 PT

Financial news for MNTA dated on 2014-05-15: Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss

Financial news for MNTA dated on 2014-05-09: Maxim Group Initiates Coverage on Momenta Pharmaceuticals, Inc. at Buy, Announces \$24.00 PT

Financial news for MNTA dated on 2014-05-07: Earlier Bank of America Upgraded Momenta Pharmaceuticals, Inc. to Buy

Financial news for MNTA dated on 2014-05-06: Form 8-K from Momenta Pharma Shows Co. Entered ATM Equity Sales Deal, May Sell Up to \$75M

Financial news for MNTA dated on 2014-05-06: Momenta Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.53) vs \$(0.55) Est; Revenue of \$10.80M vs \$8.41M Est

Financial news for MNTA dated on 2014-05-02: Momenta Pharma to Present Data Supporting Sialylation Platform

Financial news for MNTA dated on 2014-04-21: Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit

Financial news for MNTA dated on 2014-04-21: Morning Market Movers

Financial news for MNTA dated on 2014-04-21: Benzinga's Top #PreMarket Gainers

Financial news for MNTA dated on 2014-04-04: Amended 13G Filing from SAC Capital on Momenta Pharma Shows Reduced Stake from 3.89% as of Mar. 11th to 4.6%

Financial news for MNTA dated on 2014-04-03: Stocks Hitting 52-Week Lows

Financial news for MNTA dated on 2014-03-31: Market Wrap For March 31: Stocks Rally As Yellen Confirms Support For Economy

Financial news for MNTA dated on 2014-03-31: Mid-Afternoon Market Update: American Capital Rises as MannKind Shares Take a Hit

Financial news for MNTA dated on 2014-03-12: 13G Filing from SAC Capital on Momenta Pharma Shows 5.6% Stake

Financial news for MNTA dated on 2014-02-10: Momenta Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.59) vs \$(0.45) Est; Revenue of \$12.80M vs \$8.53M Est

Financial news for MNTA dated on 2013-11-06: UPDATE: Bernstein Research Reiterates on Momenta Pharmaceuticals Following 3Q13 Results Report

Financial news for MNTA dated on 2013-11-05: Momenta Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.50) vs \$(0.48) Est

Financial news for MNTA dated on 2013-08-01: Momenta Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.57) vs \$(0.46) Est; Revenue of \$4.40M vs \$8.40M Est

Financial news for MNTA dated on 2013-07-26: Bernstein Says Generic Copaxone Win Could Help Momenta Break through \$20 Level

Financial news for MNTA dated on 2013-07-26: Canaccord Genuity Upgrades Momenta Pharmaceuticals, Inc. to Buy, Raises PT to \$22.00

Financial news for MNTA dated on 2013-07-26: Momenta Pharmaceuticals Announces Potential for 2014 Market Entry of Generic Copaxone(R)

Financial news for MNTA dated on 2013-07-26: UPDATE: CAFC Issues Statement on Appeal Win by Momenta in Teva Case

Financial news for MNTA dated on 2013-07-26: Hearing Momenta Wins Appeal Against Teva

Financial news for MNTA dated on 2013-07-26: Momenta Pharmaceuticals Spikes Higher

Financial news for MNTA dated on 2013-06-25: Momenta Pharma Announces US Patent Issuance for Sialylation Technology

Financial news for MNTA dated on 2013-06-18: Wallachbeth Initiates Coverage on

Momenta Pharmaceuticals, Inc. at Buy, Announces \$17.00 PT

Financial news for MNTA dated on 2013-06-06: UBS Upgrades Momenta Pharmaceuticals, Inc. to Buy, Raises PT to \$17.00

Financial news for MNTA dated on 2013-06-06: UBS Upgrades Momenta Pharmaceuticals, Inc. to Buy

Financial news for MNTA dated on 2013-04-30: Momenta Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.48) vs \$(0.44) Est; Revenue of \$7.60M vs \$9.69M Est

Financial news for MNTA dated on 2013-03-19: UPDATE: Bank of America Downgrades Momenta Pharmaceuticals to Underperform on Valuation

Financial news for MNTA dated on 2013-03-19: Bank of America Downgrades Momenta Pharmaceuticals, Inc. to Underperform, Maintains \$14.00 PO

Financial news for MNTA dated on 2013-02-15: Momenta Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.35) vs \$(0.41) Est; Revenue of \$12.70M vs \$10.41M Est

Financial news for MNTA dated on 2013-02-15: Earnings Scheduled For February 15, 2013

Financial news for MNTA dated on 2013-01-31: Momenta Moves Higher on Report from European Medicines Agency

Financial news for MNTA dated on 2012-11-28: Stocks Hitting 52-Week Lows

Financial news for MNTA dated on 2012-11-20: Momenta Confirms Appeals Court Denied Petition, Co. to File for Rehearing at Supreme Court Level

Financial news for MNTA dated on 2012-11-20: Momenta Shares Bouncing Off Lows; Cos. Lovenox Case Loss in Appeals Court Will Stand

Financial news for MNTA dated on 2012-11-07: Momenta Pharmaceuticals Reports Q3 EPS \$-0.51 vs \$-0.27 Est

Financial news for MNTA dated on 2012-08-06: UBS Maintains Momenta Pharmaceuticals at Neutral, Lowers PT from \$15 to \$14

Financial news for MNTA dated on 2012-08-03: Hearing Appeals Court Vacates and Remands District Court Ruling in Momenta vs Amphastar Case

Financial news for MNTA dated on 2012-08-03: Momenta Decision In Lovenox Case Vacated By U.S. Appeals Court

Financial news for MNTA dated on 2012-08-02: Momenta Pharmaceuticals Reports Q2 EPS \$-0.20 vs \$-0.18 Est; Revenues \$21.9M vs \$18.99M Est

Financial news for MNTA dated on 2012-07-20: UBS Downgrades Momenta Pharmaceuticals from Buy to Neutral, Maintains PT at \$15

Financial news for MNTA dated on 2012-06-26: UBS Maintains Momenta Pharmaceuticals at Buy, Lowers PT from \$18 to \$15

Financial news for MNTA dated on 2012-06-25: Teva Beats Momenta, Mylan in Copaxone Case

Financial news for MNTA dated on 2012-06-25: Social Media Outlook for Monday June 25 (TEVA, MNTA, BMY, XOM)

Financial news for MNTA dated on 2012-06-25: Momenta Pharmaceuticals Falls 17% on Patent Infringement Ruling

Financial news for MNTA dated on 2012-06-25: Option Alert: Momenta Pharmaceuticals July 19 Call; Block Trade: 4,668 Contracts; Currently \$13.95

Financial news for MNTA dated on 2012-06-25: Morning Market Losers

Financial news for MNTA dated on 2012-06-25: UPDATE: Canaccord Genuity Downgrades Momenta Pharmaceuticals to Hold on Negative Copaxone Ruling

Financial news for MNTA dated on 2012-06-25: Benzinga's Top Pre-Market Losers

Financial news for MNTA dated on 2012-06-25: Momenta Pharmaceuticals Falls 20% Pre-Market after Losing Patent Dispute with Teva

Financial news for MNTA dated on 2012-06-25: From Earlier: Momenta Pharmaceuticals Announces Decision in Teva Patent Litigation

Financial news for MNTA dated on 2012-06-25: Canaccord Downgrades Momenta Pharmaceuticals from Buy to Hold, Lowers PT from \$17 to \$12

Financial news for MNTA dated on 2012-06-25: Canaccord Downgrades Momenta Pharmaceuticals from Buy to Hold, Lowers PT from \$17 to \$12

Financial news for MNTA dated on 2012-06-18: 5 Healthcare Stocks With The Highest Operating Margin

Financial news for MNTA dated on 2012-06-14: Option Alert: Momenta Pharmaceuticals July 17 Call; Block Trade: 2,704 Contracts; Currently \$14.75

Financial news for MNTA dated on 2012-06-06: Option Alert: Momenta Pharmaceuticals July 19 Call; Block Trade: 5,000 Contracts; Currently \$14.58

Financial news for MNTA dated on 2012-06-04: Momenta Pharmaceuticals Announces Presentation of Data Supporting Clinical Development of Novel Oncology Drug Candidate M402

Financial news for MNTA dated on 2012-06-04: Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest Cash

Financial news for MNTA dated on 2012-05-03: Momenta Pharmaceuticals Reports Q1 EPS \$-0.10 May Not Compare vs \$0.21 Est; Revenues \$24.2M vs \$40.51M Est

Financial news for MNTA dated on 2012-04-19: Notable Options Activity in Momenta Pharmaceuticals Inc

Financial news for MNTA dated on 2012-04-19: Option Alert: Momenta Pharmaceutical May 19 Call; Block Trade, 2,000 Contracts

Financial news for MNTA dated on 2012-04-18: Option Alert: Momenta Pharmaceuticals May 19 Call; Block Trade, 4,577 Contracts

Financial news for MNTA dated on 2012-04-10: UBS Maintains Momenta Pharmaceuticals at Buy, Lowers PT from \$19.5 to \$18

Financial news for MNTA dated on 2012-02-09: Momenta Pharmaceuticals Reports Q4 EPS \$(0.02) vs \$0.27 Est; Revenues \$26.10M vs \$38.59M Est

Financial news for MNTA dated on 2012-01-28: S&P Indices Announces Change to US Index

Financial news for MNTA dated on 2012-01-27: Momenta Pharmaceuticals Trading 3% Higher on Heavy Volume; Currently at \$15.58

Financial news for MNTA dated on 2012-01-26: UPDATE: Momenta Pharmaceuticals Motion for Preliminary Injunction Against Amphastar Pharmaceuticals & Watson Pharmaceuticals

Financial news for MNTA dated on 2012-01-26: Hearing UBS Says Buy Momenta Now

Financial news for MNTA dated on 2012-01-26: Momenta Seeking to Block Amphastar's Generic Lovenox

Financial news for MNTA dated on 2012-01-05: Benzinga's Top ETF Gainers, January 5th (AGA, SOXL, FAS, XBI)

Financial news for MNTA dated on 2012-01-02: Weekly Homework: Wipe The 2011 Slate Clean (With Economic Calendar and Stock Radar)

Financial news for MNTA dated on 2011-12-22: Baxter and Momenta Announce Collaboration to Develop and Commercialize Follow-On Biologics; Baxter to Make Upfront Cash Payment of \$33M

Financial news for MNTA dated on 2011-12-15: Benzinga's M&A Chatter for Thursday December 15, 2011

Financial news for MNTA dated on 2011-12-05: Momenta Pharmaceuticals Acquires Assets From Virdante Pharmaceuticals

Financial news for MNTA dated on 2011-11-08: Bank of America Merrill Lynch Maintains Momenta Pharmaceuticals Neutral, PO To \$16

Financial news for MNTA dated on 2011-11-08: Bank of America Raises PO on Momenta Pharmaceuticals to \$16

Financial news for MNTA dated on 2011-11-07: Momenta Pharmaceuticals Reports Q3 EPS \$1.18 vs \$1.30 Est; Revenues \$87.9M vs \$90.92M Est

Financial news for MNTA dated on 2011-11-01: Monday's NASDAQ Winners: Sify

Technologies, Rediff.com, Momenta Pharmaceuticals, China Valves Technology

Financial news for MNTA dated on 2011-10-31: End-of-Day Market Summary for October 31, 2011

Financial news for MNTA dated on 2011-10-31: Top Movers; Sify Technologies up 30%

Financial news for MNTA dated on 2011-10-28: Momenta Pharmaceuticals Rises 20% After-Hours on Injunction News

Financial news for MNTA dated on 2011-10-28: Momenta Pharmaceuticals Obtains Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd.

Financial news for MNTA dated on 2011-10-24: Momenta Pharmaceuticals Announces That Launch of Authorized Generic Lovenox Triggers Change in Collaboration Terms

Financial news for MNTA dated on 2011-10-09: Watson Pharmaceuticals Provides Update on District Court Order Concerning Generic Version of LOVENOX

Financial news for MNTA dated on 2011-09-30: Momenta Pharmaceuticals Files for Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd.

Financial news for MNTA dated on 2011-09-23: UBS Upgrades Momenta Pharmaceuticals, Trims PT

Financial news for MNTA dated on 2011-09-22: Hearing UBS Upgrades Momenta Pharmaceuticals from Neutral to Buy with \$16PT

Financial news for MNTA dated on 2011-09-21: Momenta Pharma Sues International Medical Systems; Sues Watson for Patent Infringement; Cites Methods of Producing Enoxaparin Sodium; Sues Amphastar for Patent Infringement

Financial news for MNTA dated on 2011-09-20: UPDATE: Goldman Sachs Lowers Price Target on Momenta Pharmaceuticals to \$12

Financial news for MNTA dated on 2011-09-20: Financial Breakfast: Morning News Summary for September 20, 2011

Financial news for MNTA dated on 2011-09-20: Benzinga's Top Upgrades

Financial news for MNTA dated on 2011-09-20: Goldman Sachs Lowers PT on Momenta Pharmaceuticals to \$12

Financial news for MNTA dated on 2011-09-20: Bank of America Upgrades Momenta Pharmaceuticals to Neutral, Lowers PO to \$15

Financial news for MNTA dated on 2011-09-19: Midday Losers; Momenta Pharmaceuticals Down -23.32%

Financial news for MNTA dated on 2011-09-19: FDA Approves Amphastar's Generic Lovenox; Momenta Spiking Lower on News

Financial news for MNTA dated on 2011-09-19: Momenta Pharmaceuticals Spiking Lower on Heavy Volume

Financial news for MNTA dated on 2011-08-24: Notable Put Options Activity in Momenta Pharmaceuticals

Financial news for MNTA dated on 2011-08-19: Notable Call Options Activity in Momenta Pharmaceuticals

Financial news for MNTA dated on 2011-08-04: Momenta Pharmaceuticals Reports Q2 EPS \$1.26 vs \$1.13 Est; Revenues \$87.5M vs \$79.29M Est

Financial news for MNTA dated on 2011-07-11: Oppenheimer Has Positive Stance On Momenta Pharmaceuticals

Financial news for MNTA dated on 2011-06-28: UPDATE: Bank of America Merrill Lynch Initiates Momenta Pharmaceuticals at Underperform

Financial news for MNTA dated on 2011-06-28: Bank of America Initiates Momenta Pharmaceuticals At Underperform, \$19 PO

Financial news for MNTA dated on 2011-06-20: Momenta Pharmaceuticals Study Showing M402 Inhibits Tumor Metastasis in Multiple Murine Oncology Models Published in PLoS One



Financial news for MNTA dated on 2011-06-20: Wedbush Reiterates PT, Rating On MNTA

Financial news for MNTA dated on 2011-06-09: Options Brief: Momenta Pharmaceuticals

Financial news for MNTA dated on 2011-05-10: Puts Purchased on Momenta Pharmaceuticals (MNTA)

Financial news for MNTA dated on 2011-05-05: Momenta Pharma Reports EPS of \$1.13 vs. \$0.91 Estimate; Revenues \$78.2M vs. \$67.12M Estimate (MNTA)

Financial news for MNTA dated on 2011-02-28: Long MNTA and CPWR

Financial news for MNTA dated on 2011-02-16: PRE-MARKET MOVERS: (MCRL), (MNTA), (CYAN), (RVSN)

Financial news for MNTA dated on 2011-02-15: Options Brief: Momenta Pharmaceuticals (MNTA)

Financial news for MNTA dated on 2011-02-08: Momenta Pharma Awarded U.S. Patent For Glatiramer Acetate Methods (MNTA)

Financial news for MNTA dated on 2011-01-25: Momenta Pharmaceuticals Falls 16% (MNTA, TEVA)

Financial news for MNTA dated on 2011-01-24: Timers Market 01-24-2011

Financial news for MNTA dated on 2011-01-20: 4 Drug Stocks Poised to Stage Comeback

Financial news for MNTA dated on 2010-12-22: Wednesday's Put/Call Ratio Leaders (CVBF, MNTA, JDSU, NG, BSX)

Financial news for MNTA dated on 2010-12-22: Options Brief: Momenta Pharmaceuticals (MNTA)

Financial news for MNTA dated on 2010-12-21: Tuesday's Put/Call Ratio Leaders (ACL, NRG, MNTA, NOG, GRMN)

Financial news for MNTA dated on 2010-12-20: Puts Purchased on Momenta Pharmaceuticals (MNTA)

Financial news for MNTA dated on 2010-12-20: Goldman Sachs Initiates Neutral Rating on Momenta Pharmaceuticals (MNTA)

Financial news for MNTA dated on 2010-12-20: Goldman Sachs Initiates MNTA Coverage With A Neutral Rating, \$15 PT

Financial news for MNTA dated on 2010-12-15: Good Data on Teva's Laquinimod - Analyst Blog

Financial news for MNTA dated on 2010-12-15: Good Data on Teva's Laquinimod - Analyst Blog

Financial news for MNTA dated on 2010-12-09: Options Brief: Momenta Pharmaceuticals (MNTA)

Financial news for MNTA dated on 2010-12-08: Benzinga's Top Pre-Market NASDAQ Losers (MNTA, NFLX, ASML, ERIC)

Financial news for MNTA dated on 2010-11-16: Tuesday's Put/Call Ratio Leaders (CADX, ROC, LH, MNTA, NVS)

Financial news for MNTA dated on 2010-10-21: Benzinga's Top Pre-Market NASDAQ Gainers (NLST, NFLX, EBAY, MNTA)

Financial news for MNTA dated on 2010-10-12: Tuesday's Put/Call Ratio Leaders (SNI, VIA.B, OCR, DLR, MNTA)

Financial news for MNTA dated on 2010-09-15: Mad Money Lightning Round OT: Cramer Can't Recommend SandRidge Energy (SD) (MNTA, FTR, CTL, WIN, SD)

Financial news for MNTA dated on 2010-09-07: Wedbush Securities Sees Almost 100% Upside In Momenta Pharmaceuticals (MNTA)

Financial news for MNTA dated on 2010-09-07: Momenta Loses Generic Copaxon Bid (MNTA, TEVA, BIIB)

Financial news for MNTA dated on 2010-08-30: SNY Seeks to Expand Vaccine Label - Analyst Blog

Financial news for MNTA dated on 2010-08-26: Benzinga's Volume Movers (MNTA, HAIN, BRLI, PAAS)

Financial news for MNTA dated on 2010-08-26: Unconfirmed chatter that (TEVA)will acquire Momenta Pharmaceuticals Inc. (MNTA) at \$25.00 a share

Financial news for MNTA dated on 2010-08-26: Benzinga's Top Pre-Market NASDAQ Gainers (MNTA, SOLF, NFLX, ARNA)

Financial news for MNTA dated on 2010-08-02: Momenta Pharmaceuticals Up Nearly 5% (MNTA)

Financial news for MNTA dated on 2010-08-02: Momenta Pharmaceuticals Narrows Loss (MNTA)

Financial news for MNTA dated on 2010-07-27: Momenta Pharmaceuticals Falling On Heavy Volume (NASDAQ:MNTA)

Financial news for MNTA dated on 2010-07-27: Benzinga's Top Pre-Market NASDAQ Losers (MNTA, WERN, NVDA, ARMH)

Financial news for MNTA dated on 2010-07-26: Benzinga's Volume Movers (MNTA, ONXX, IDSA, GENZ)

Financial news for MNTA dated on 2010-07-23: Momenta Pharmaceuticals Resumes Trading, Skyrocketing (MNTA)

Financial news for MNTA dated on 2010-07-23: Momenta Pharma Doubles on Lovenox News (MNTA)

Financial news for MNTA dated on 2010-07-23: Pharma Names Rallying on FDA Decision about Lovenox (INSM, MNTA, ABC, MHS)

Financial news for MNTA dated on 2010-07-23: FDA Approves Momenta Pharmaceuticals Drug

Financial news for MNTA dated on 2010-07-23: Momenta Pharma Trading Halted (MNTA)

Financial news for MNTA dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for MNTA dated on 2010-01-22: Top Narrow Based Indexes Today

Financial news for MNTA dated on 2010-01-22: Benzinga's Volume Movers (MNTA, ISRG, TRGL, IPGP, JCOM)

Financial news for MNTA dated on 2009-11-10: Teva Pharma (TEVA) moves to expand scope of suit for use of its generic version